Anvisa approves butantan vaccine against chikungunya for use in Brazil

BySimon Rousseau Posted on
A Anvisa informa que a vacina, de dose única, será indicada para a prevenção da doença em pessoas com 18 anos ou mais.

The National Health Surveillance Agency (Anvisa) approved the registration of the first vaccine against chikungunya, as resolution published in the Official Gazette of the Union (DOU) This Monday, 14. This is the immunizer IXCHIQ, developed by the Butantan Institute.

Anvisa reports that the unique dose vaccine will be indicated for disease prevention in people aged 18 or older. The substance, however, is contraindicated for pregnant women, immunodeficient or immunosuppressed people, warns the regulatory organ.

“The Ixchiq vaccine has been shown to induce robust production of neutralizing antibodies against the virus that causes chikungunya in clinical studies that evaluated adults and adolescents who have received a dose of immunizer,” the agency quotes.

Read more:  Brazil has not reduced maternal mortality since 2000; Rate falls into neighbors
Simon Rousseau
Simon Rousseau

Hello, I'm Simon, a 39-year-old cinema enthusiast. With a passion for storytelling through film, I explore various genres and cultures within the cinematic universe. Join me on my journey as I share insights, reviews, and the magic of movies!